Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $190

巴克莱银行维持泰尼特(THC.US)买入评级，上调目标价至190美元

moomoo资讯 · 2024/11/08 03:31 · 评级/大行评级

Barclays analyst Andrew Mok CFA maintains $Tenet Healthcare (THC.US)$ with a buy rating, and adjusts the target price from $171 to $190.

According to TipRanks data, the analyst has a success rate of 42.1% and a total average return of -5.4% over the past year.

AnalystRecentRatingAutoNews_201836_20241108_895a75317c6ce2edded518f023d220daf61922b7_1731144625313520_mm_en

Furthermore, according to the comprehensive report, the opinions of $Tenet Healthcare (THC.US)$'s main analysts recently are as follows:

The outlook for hospitals was exceptionally positive in 2024, and this trend appears set to continue into 2025. There is potential for earnings growth for both HCA and Tenet, provided that the assumptions for organic growth are sensible.
Following Tenet Healthcare's Q3 earnings, revisions to models and detailed earnings assessments for each hospital were noted, with most core adjustments being relatively minor. Changes are primarily driven by the effects of hurricane impacts and updated assumptions regarding Medicaid supplemental payments.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

巴克莱银行分析师Andrew Mok CFA维持$泰尼特 (THC.US)$买入评级，并将目标价从171美元上调至190美元。

根据TipRanks数据显示，该分析师近一年总胜率为42.1%，总平均回报率为-5.4%。

AnalystRecentRatingAutoNews_201836_20241108_895a75317c6ce2edded518f023d220daf61922b7_1731144625313520_mm_sc

此外，综合报道，$泰尼特 (THC.US)$近期主要分析师观点如下：

2024年，医院的前景异常乐观，这种趋势似乎将持续到2025年。只要有机增长的假设合理，HCA和Tenet都有可能实现盈利增长。
继Tenet Healthcare公布第三季度财报之后，注意到对每家医院的模型和详细收益评估进行了修订，大多数核心调整相对较小。变化主要是由飓风影响的影响以及有关医疗补助补充补助金的最新假设推动的。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $190

Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $190

风险及免责提示

声明